Startup profile · funding coverage
Maze Therapeutics funding, valuation and investors
Clinical-stage biotech using human genetics to develop precision small-molecule medicines.
Keep track of Maze Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series D
$115M · December 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$306M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · South San Francisco, California
Investors in latest funding
Lead: Frazier Life Sciences
Other: Andreessen Horowitz , General Catalyst
Overview
Maze Therapeutics is a South San Francisco biotech founded in 2018 that uses its Compass platform to link human genetic variants to therapeutic targets, then develops precision small-molecule medicines. The company raised a $191M Series A in February 2019 with ARCH Venture Partners and Third Rock Ventures, and a $115M Series D in December 2024 co-led by Frazier Life Sciences and Deep Track Capital with Andreessen Horowitz, General Catalyst, and existing investors participating.
Why Maze Therapeutics is interesting
Maze's Compass platform maps genetic variants to druggable pathways — a16z joined ARCH and Third Rock across $496M+ raised as MZE829 and other programs advanced toward clinic in renal and cardio-metabolic disease.
Product & use cases
Maze's Compass platform integrates human genetic data, functional genomics, and small-molecule discovery to identify and validate targets with genetic evidence of disease causality — reducing clinical trial risk versus traditional target selection.
- Developing precision therapies for renal disease based on genetic pathway validation
- Cardio-metabolic programs targeting genetically validated pathways
- Partnering with pharma on genetically anchored drug discovery
Key facts
- Series D (Dec 2024): $115M co-led by Frazier Life Sciences and Deep Track (company IR)
- Series A (Feb 2019): $191M with ARCH and Third Rock
- Compass platform links genetic variants to druggable pathways
- Clinical-stage programs in renal and cardio-metabolic disease
Funding history (newest first)
Series D
2024-12 $115M- Frazier Life Sciences (lead)
- Andreessen Horowitz (participant)
- General Catalyst (participant)
Series A
2019-02 $191MSource: https://www.mazetx.com/news/maze-therapeutics-launches
Investors in our directory
Funds linked from Maze Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Human genetics as target filter — Compass prioritizes targets with causal genetic evidence, a strategy ARCH and Third Rock pioneered and a16z joined at scale via large Series A/B rounds.
Genetics-guided drug discovery is proven (PCSK9, etc.) but capital-intensive. Maze's $496M+ raised reflects investor belief Compass can industrialize genetic target selection across multiple programs simultaneously.
-
Regeneron Genetics Center partners incumbent
Big pharma genetics franchises; Maze competes as focused genetics-native biotech.
-
Insitro adjacent
ML-driven drug discovery with different modality mix; overlaps on genetics-informed target ID.
-
Traditional target discovery alternative
Phenotypic and literature-based approaches without systematic genetic validation.
Notable stories
- Maze launched in 2019 with one of biotech's largest Series A rounds ($191M) — signaling genetics-native drug discovery as a fundable platform, not single-asset stories.
- a16z Bio + Health participation across rounds reflects crossover investor interest in computationally guided biotech beyond traditional life-science VC syndicates.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Maze Therapeutics's financing or category context.
FAQs about Maze Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.